Biophytis S.A. (6XB3.F)

0.5800 -0.0500 (-7.94%) At close: 09:50PM CEST

Biophytis S.A.

Sorbonne University
Bâtiment A 4ème étage 4 place Jussieu Cedex 05
Paris 75005
France
33 1 44 27 23 00
https://www.biophytis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 22

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stanislas Veillet Ph.D.	Chairman of the Board & CEO	349k	N/A	1965
Mr. Nicolas Fellmann	Chief Financial Officer	N/A	N/A	1968
Mr. Waly Dioh Ph.D.	Chief Clinical Operating Officer	N/A	N/A	1969
Dr. Pierre J. Dilda Ph.D.	Chief Scientific Officer	N/A	N/A	1970
Dr. Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	N/A	N/A	1946
Dr. Rob van Maanen FFPM, M.B.A., M.D.	Chief Medical Officer	N/A	N/A	1971
Mr. Edouard Bieth	Chief Business Officer	N/A	N/A	1980
Ms. Chiara Baccelli	Chief Pharmaceutical Operations Officer & Quality Assurance Director	N/A	N/A	N/A
Ms. _ Teylan	Financial Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Corporate governance

Biophytis S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.